Abstract:Background: Immunotherapy functions by leveraging immunoregulation drugs to bolster the immune system's capacity to identify and eliminate cancerous cells. In contrast to radiotherapy and chemotherapy, immunotherapy exhibits diminished side effects, heightened efficacy, and prolonged survival rates. Nevertheless, meticulous exploration into the determinants governing the advantageous effects of immunotherapy among patients who have previously undergone multiple prior therapies has yet to be conducted. Albumin (ALB) as a nutritional indicator has not been thoroughly studied for its prognostic effect on efficacy or survival. This study aims to identify factors that influence treatment outcomes among patients undergoing third-line or later immunological therapies. Methods: A cohort of 250 lung cancer patients undergoing toripalimab or tislelizumab immunotherapy was the focal point of data collection. The determination of the median value facilitated the establishment of a cut-off point, enabling the categorization of continuous variables. After data collection, a series of statistical analyses of various clinical factors at baseline were performed, including nonparametric tests, logistic regression, and Cox proportional risk modeling. The last follow-up was in May 2022. The primary study endpoint was overall survival (OS). Results: A total of 250 patients were enrolled in the study, of which 129 patients received first- or second-line immunotherapy and 121 patients received third-line or subsequent immunotherapy. According to Cox multifactor regression analysis, in patients receiving either first- or second-line therapy, the ALB level exhibited negligible prognostic relevance (P>0.05). However, in patients subjected to immunotherapy beyond the second line, the ALB level manifested significant prognostic importance (P=0.039). Notably, patients demonstrating elevated ALB levels achieved a higher disease control rate (DCR) (70.0% vs. 52.5%, P=0.05) and displayed a tendency towards a heightened objective response rate (ORR) (20.0% vs. 16.4%, P=0.61) in comparison to those with lower ALB levels. Conclusions: Among patients undergoing immunotherapy in the third line or subsequent treatment phases, elevated ALB levels in baseline correlated with DCR and OS. Thus, the pre-immunotherapy ALB level emerges as an autonomous predictor of OS in patients subjected to third- or later line immunotherapy interventions.

Prognostic value of serum albumin level in re-irradiation for patients with local recurrent esophageal carcinoma

Prognostic Impact of Serum Albumin Levels on the Recurrence of Stage I Non-Small Cell Lung Cancer

Low pretherapeutic serum albumin as a risk factor for poor outcome in esophageal squamous cell carcinomas.

Clinical Significance of Albumin-Bilirubin Grade in Thoracic Esophageal Squamous Cell Carcinoma

Influence of serum albumin to prognosis of colonic neoplasms after surgery

Pretreatment Serum Albumin and Neutrophil-to-Lymphocyte Ratio for Predicting Overall Survival in Esophageal Cancer Patients

Association between preoperative serum albumin and prognosis in patients with adrenocortical carcinoma after primary resection: a retrospective study

Prognostic value of albumin-bilirubin score in pancreatic cancer patients after pancreatoduodenectomy with liver metastasis following radiofrequency ablation

Prognostic significance of pretreatment albumin/globulin ratio in patients with hepatocellular carcinoma.

Survival Benefit of Re-Irradiation in Esophageal Cancer Patients with Locoregional Recurrence: a Propensity Score-Matched Analysis

Impact of Post‐operative Serum Albumin Level on Anastomotic Leakage after Transthoracic Oesophagectomy for Oesophageal Squamous Cell Carcinoma

The prognostic role of albumin levels in lung cancer patients receiving third-line or advanced immunotherapy: a retrospective study

Research progress and value of albumin-related inflammatory markers in the prognosis of non-small cell lung cancer: a review of clinical evidence

Prognosis Analysis of Esophageal Carcinoma Patients with Tumor Loco-Regional Recurrence after Curative Surgery

Association of Preoperative Serum Albumin Level with Clinicopathologic Features and Prognosis in Gastric Stump Cancer

Predictive Value of GINI and ALBI Grades in Esophageal Cancer Receiving Chemoradiotherapy

Low Preoperative Albumin-to-Globulin Ratio Is a Marker of Poor Prognosis in Patients With Esophageal Cancer

Influence of red blood cell transfusion with radiation on serum inflammatory factors and prognosis of perioperative patients with esophageal carcinoma

Albumin to Gamma-Glutamyltransferase Ratio As a Prognostic Indicator in Intrahepatic Cholangiocarcinoma after Curative Resection.

Prognostic significance of albumin-bilirubin score in patients with unresectable hepatocellular carcinoma undergoing combined immunotherapy and radiotherapy

Serum albumin level at diagnosis of diffuse large B-cell lymphoma: an important simple prognostic factor